Abstract. The present study aimed to investigate the regulatory mechanisms by which interleukin (IL)-22 regulates cisplatin (DDP) sensitivity in osteosarcoma cells. Firstly, reverse transcription-quantitative (RT-q) PCR and western blotting demonstrated that IL-22 expression was significantly increased in osteosarcoma tissues and cell lines compared with the adjacent normal tissues and the normal osteoblast hFOB1.19 cells. Subsequently, the MG63 osteosarcoma cell line and cisplatin-resistant MG63/DDP osteosarcoma cell line were treated with different concentrations of cisplatin (2.5, 5.0, 10, 20, 40 and 80 µg/ml), and the half maximal inhibitory concentration (IC_{50}) was calculated based on the MTT assay. The results showed that the IC_{50} of DDP in MG63/DDP cells was significantly higher than that in MG63 cells. Furthermore, IL-22 expression was higher in MG63/DDP cells compared with MG63 cells. Subsequently, the effects of IL-22 down-regulation and overexpression on MG63/DDP and MG63 cells were assessed using the MTT assay, flow cytometry, RT-qPCR and western blotting. The IL-22 small interfering (si) RNA in MG63/DDP cells significantly decreased the IC_{50} of DDP and decreased the cell viability of MG63/DDP cells. Furthermore, IL-22 RNA interference decreased BCl-2 expression and phosphorylation of STAT3, induced apoptosis, and increased the expression of apoptosis-associated genes, and thereby mediating the sensitivity of osteosarcoma cells to cisplatin.

Introduction

Osteosarcoma is a malignant bone tumor derived from mesenchymal tissue (1) and usually occurs in adolescents. If treatment is not timely, 80% of patients with osteosarcoma develop lung metastasis, thus resulting in a high mortality rate (2). However, advances in chemotherapy and advanced orthopedic surgical techniques have significantly increased the survival rates (2,3).

Chemotherapy for osteosarcoma is based on cisplatin, which kills the majority of tumor cells, decreases recurrence rate and improves the 5-year survival rate of patients (4,5). However, some patients experience tumor recurrence and metastasis due to cisplatin resistance, which seriously affect the effectiveness of treatment and the survival rate (6,7). The current mechanism of cisplatin resistance remains largely unclear and decreasing tumor drug resistance has become an important aspect in the treatment of osteosarcoma in recent years.

Interleukin (IL)-22 is a cytokine discovered by Dumoutier et al (8) in 2000. It encodes an α helix protein with a structure that is ~23% homologous to IL-10 and belongs to the IL-10 family (9). A previous study has shown that IL-22 may regulate the growth of osteosarcoma cells (10). However, whether IL-22 regulates cisplatin sensitivity in osteosarcoma cells remains unclear. Therefore, the present study was based on the hypothesis that IL-22 may enhance the chemosensitivity of osteosarcoma cells to cisplatin.

The purpose of the present study was to investigate whether IL-22 could regulate cisplatin sensitivity in osteosarcoma cells, and to further explore its underlying mechanism.

Materials and methods

Clinical samples and ethics statement. A total of 30 paired human osteosarcoma tissues and adjacent normal tissues (2 cm from the tumor lesion) were obtained from 30 patients (age range, 20-69 years old; female to male ratio, 17:13) with osteosarcoma at Suzhou Municipal Hospital between May 2016 and May 2018. All the tissue samples were re-evaluated according to the World Health Organization classification by
2 pathologists. The current study was approved by the institutional review board of the Suzhou Municipal Hospital and patients provided written informed consent.

**Cell culture.** The normal osteoblast cell line hFOB1.19 was used in the present study. Additionally, the human osteosarcoma cell lines MG63, SOSP-9607, U2OS and SAOS2 were also investigated.

All cells were cultured in Dulbecco's Modified Eagle Medium (DMEM) (Gibco; Thermo Fisher Scientific, Inc.) supplemented with 10% fetal bovine serum (FBS; Gibco; Thermo Fisher Scientific, Inc.) at 37°C and 5% CO₂.

The cisplatin-resistant osteosarcoma cell line MG63/DDP was generated by continuous stimulation of MG63 cells with progressively increasing concentrations of cisplatin (Sigma-Aldrich; Merck KGaA), according to a previous study (11).

MG63 and MG63/DDP cells were treated with cisplatin at different concentrations (2.5, 5.0, 10, 20, 40 and 80 µg/ml) for 24 h to calculate the IC₅₀ value of cisplatin for MG63 and MG63/DDP cells.

**Reverse transcription-quantitative (RT-q) PCR.** Total RNA was extracted from osteosarcoma tissue samples and the osteosarcoma cell lines using TRIZol reagent (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer's protocol. The concentration of RNA was detected using a Nanodrop2000 spectrophotometer (Thermo Fisher Scientific, Inc.). The RNA samples were stored at -80°C for future use. Subsequently, cDNA was synthesized using a miScript Reverse Transcription kit (Qiagen), according to the manufacturer's protocol. The QuantiFast SYBR Green PCR kit (Qiagen) was used to perform the qPCR in a CFX Connect Real-Time system (Bio-Rad, Laboratories, Inc.) with the SignalFire™ enhanced chemiluminescence reagent (cat. no. 6883; Cell Signaling Technology, Inc.). Image J 1.38X (National Institutes of Health) was used to perform the densitometry analysis.

**MTT assay.** Cell viability was measured using the MTT assay (Sigma-Aldrich; Merck KGaA). The cells were seeded into 96-well plates at a density of 5,000 cells/well and incubated overnight in DMEM medium supplemented with 10% FBS. Cells were treated as follows: i) MG63 and MG63/DDP cells were treated with cisplatin at different concentrations (2.5, 5.0, 10, 20, 40 and 80 µg/ml) for 24 h; ii) MG63/DDP cells were transfected with 0.2 µM IL-22 siRNA or 1 µM control siRNA for 48 h; and iii) MG63 cells were transfected with 1 µg IL-22 overexpression plasmid or 1 µg control plasmid for 48 h, the cell viability was determined. Briefly, 20 µl MTT solution (5 mg/ml in distilled water) was added to each well, and the cells were incubated for another 4 h at 37°C, after which the medium was removed. Subsequently, 150 µl dimethyl sulfoxide (Sigma-Aldrich; Merck KGaA) was added, and the optical density was measured at 490 nm on a multifunctional micro-plate reader. The experiment was repeated three times.

**Cell transfection.** Cells were seeded onto 6-well plates (1x10⁴ cells/well) and cultured at 37°C for 24 h. Then, MG63/DDP cells were transfected with 0.2 µM IL-22 siRNA (cat no. sc-39664; Santa Cruz Biotechnology, Inc.) or 1 µM control siRNA (scrambled control; cat no. sc-36869; Santa Cruz Biotechnology, Inc.). MG63 cells were transfected with 1 µg IL-22 overexpression plasmid or 1 µg control plasmid for 48 h, the cell viability was determined. Briefly, 20 µl MTT solution (5 mg/ml in distilled water) was added to each well, and the cells were incubated for another 4 h at 37°C, after which the medium was removed. Subsequently, 150 µl dimethyl sulfoxide (Sigma-Aldrich; Merck KGaA) was added, and the optical density was measured at 490 nm on a multifunctional micro-plate reader. The experiment was repeated three times.

**Flow cytometry assay.** Cells were digested using 0.2% trypsin, washed with PBS and fixed with the 70% ethanol overnight at 4°C. Cells were subsequently stained using the Annexin

Western blotting. Cells were washed twice with phosphate buffer saline (PBS), collected and lysed in RIPA buffer (Beyotime Institute of Biotechnology). Proteins were quantified using a bicinecinonic acid protein assay kit (Beyotime Institute of Biotechnology) following the manufacturer's protocol. The cell lysates (40 µg protein per lane) were separated on a 10% gel by SDS-PAGE and transferred onto polyvinylidene fluoride membranes (Bio-Rad Laboratories, Inc.). After blocking non-specific binding with tris buffered saline-Tween (0.1% Tween) containing 5% non-fat milk for 1 h at room temperature, the membranes were immunoblotted with the following primary antibodies: IL-22 (cat. no. Ab181007; Abcam), Bel-2 (cat. no. 4223; Cell Signaling Technology, Inc.), Bax (cat. no. 5023; Cell Signaling Technology, Inc.), p-STAT3 (cat. no. 9145; Cell Signaling Technology, Inc.), STAT3 (cat. no. 12640; Cell Signaling Technology, Inc.) and β-actin (cat. no. 4970; Cell Signaling Technology, Inc.) at 4°C overnight (all 1:1,000). Subsequently, the membranes were incubated with horseradish peroxidase-conjugated goat anti-rabbit secondary antibodies (1:2,000; cat. no. 7074; Cell Signaling Technology, Inc.) for 2 h at room temperature. The protein bands were detected using the ChemiDOC™ system (Bio-Rad, Laboratories, Inc.) with the SignalFire™ enhanced chemiluminescence reagent (cat. no. 6883; Cell Signaling Technology, Inc.). Image J 1.38X (National Institutes of Health) was used to perform the densitometry analysis.
V-fluorescein isothiocyanate (FITC)/propidium iodide (PI) kit [cat no. 70-AP101-100; Hangzhou Multi Sciences (Lianke) Biotech Co., Ltd], according to the manufacturer's instructions. The apoptosis rate was determined using a FACS Calibur flow cytometer (BD Biosciences) and analyzed with the Cell Quest software (version 5.1; BD Biosciences). The assay was performed in triplicate.

Statistical analyses were performed using GraphPad Prism software (version 5.0; GraphPad Software, Inc.). All quantitative data are expressed as the mean ± standard deviation. Comparisons between two groups were analyzed using the unpaired Student's t-test. Comparisons of multiple groups were performed by the one-way ANOVA followed by Tukey's post-hoc test. P<0.05 was used to indicate a statistically significant difference.

**Results**

**IL-22 expression is significantly elevated in osteosarcoma tissues and cell lines.** RT-qPCR and western blotting were used to detect the expression of IL-22 in osteosarcoma tissue samples and osteosarcoma cell lines. The results showed that IL-22 protein (Fig. 1A) and mRNA (Fig. 1B) expression levels were significantly increased in osteosarcoma tissues compared with the adjacent normal tissues. Compared with the normal osteoblast hFOB1.19 cells, the protein level of IL-22 was increased in osteosarcoma cell lines (Fig. 1C), and was the highest in MG63 cells. RT-qPCR revealed similar changes in mRNA levels (Fig. 1D).

**IC_{50} value of DDP is significantly higher in MG63/DDP cells compared with MG63 cells.** MG63 and MG63/DDP cells were treated with cisplatin at different concentrations (2.5, 5.0, 10, 20, 40 and 80 µg/ml) for 24 h, and the MTT assay was used to assess cell viability (Fig. 2A) and calculate the IC_{50} values (Fig. 2B). The results showed that the IC_{50} value of DDP in MG63/DDP cells was significantly higher than that in MG63 cells (Fig. 2B).

**IL-22 expression is significantly higher in MG63/DDP cells compared with MG63 cells.** Western blotting and RT-qPCR were used to detect the expression levels of IL-22 in MG63 and MG63/DDP cells. The results showed that IL-22 expression was significantly higher in MG63/DDP cells compared with MG63 cells (Fig. 2C and D).

**IL-22 significantly affects the IC_{50} value of DDP in MG63/DDP cells and MG63 cells.** MG63/DDP cells were transfected with IL-22 siRNA or control siRNA, and MG63 cells were transfected with IL-22 plasmid or control plasmid for 48 h, followed by RT-qPCR and western blotting to detect transfection efficiency. The results showed that IL-22 siRNA resulted in markedly decreased IL-22 protein and mRNA expression in MG63/DDP cells (Fig. 3A and B). The transfected MG63/DDP or MG63 cells were subsequently treated with cisplatin at...
differences concentrations (2.5, 5.0, 10, 20, 40 and 80 µg/ml) for 24 h. The cell viability inhibition rate (Fig. 3C) was measured and IC₅₀ values (Fig. 3D) were calculated based on the MTT assay. The results showed that IL-22 siRNA significantly enhanced the inhibition of cell viability rate and decreased the IC₅₀ value of DDP in MG63/DDP cells (Fig. 3C and D). Moreover, the IL-22 overexpression plasmid significantly increased IL-22 protein (Fig. 3E) and mRNA (Fig. 3F) expression in MG63 cells. The IL-22-plasmid significantly decreased the cell viability inhibition rate and increased the IC₅₀ value of DDP in MG63 cells (Fig. 3G and H).

Effects of IL-22 on cell viability, apoptosis and the STAT3 signaling pathway in MG63/DDP and MG63 cells. MG63/DDP cells were transfected with IL-22 siRNA or control siRNA and MG63 cells were transfected with the IL-22 overexpression plasmid or control plasmid for 24 h. Subsequently, cell viability was detected by the MTT assay and cell apoptosis was detected by flow cytometry. Furthermore, western blotting was used to detect the protein expression levels of apoptosis-associated factors (Bcl-2, Bax and cleaved caspase-3), STAT3 and p-STAT3. RT-qPCR was used to detect the mRNA expression of Bcl-2, Bax and STAT3. The results showed that IL-22 siRNA significantly decreased MG63/DDP cell viability (Fig. 4A) and induced apoptosis (Fig. 4B and C). IL-22 siRNA significantly decreased the mRNA expression of Bcl-2 (Fig. 4E) and significantly enhanced Bax mRNA levels (Fig. 4F). IL-22 siRNA had no significant effects on the protein and mRNA levels of STAT3 in MG63/DDP cells (Fig. 4D, G and L).

The IL-22 overexpression plasmid significantly increased MG63 cell viability (Fig. 5A), inhibited apoptosis (Fig. 5B and C), increased BCl-2 expression (Fig. 5D, E and H), decreased Bax (Fig. 5D, F and I) and cleaved caspase-3 expression (Fig. 5D and J) and increased p-STAT3 expression (Fig. 5D and K). There were no significant changes in the protein and mRNA levels of STAT3 among the different groups (Fig. 5D, G and L).

Discussion

Osteosarcoma has a poor prognosis and is associated with increased recurrence rate and risk of metastasis (13). However, the pathogenesis of osteosarcoma remains largely unknown.

Cisplatin induces apoptosis by activating the endogenous and exogenous apoptotic signaling pathways, and participates in multiple signal transduction pathways to inhibit and kill tumor cells (14). However, cisplatin is associated with toxic side effects and drug resistance. The present study demonstrated that the IC₅₀ value of DDP in MG63/DDP cells was significantly higher than that of MG63 cells, indicating that these cells were resistant to DDP.

Evidence shows that elevated levels of IL-22 in several malignancies is detrimental (15-18). In the present study, the
expression of IL-22 in osteosarcoma tissue samples and osteosarcoma cell lines was determined. The results showed that IL-22 expression was significantly increased in osteosarcoma tissues and cell lines, which was consistent with a previous...
Figure 4. Effects of IL-22 on cell viability, apoptosis and the STAT3 signaling pathway in MG63/DDP cells. MG63/DDP cells were transfected with IL-22 siRNA or control siRNA for 48 h. (A) The MTT assay was used to detect cell viability. (B) Flow cytometry was used to detect cell apoptosis and (C) the apoptosis rate was calculated. (D) Western blotting was used to detect the protein expression of Bcl-2, Bax, cleaved caspase-3, p-STAT3 and STAT3. Reverse transcription-quantitative PCR was used to detect mRNA expression of (E) Bcl-2, (F) Bax and (G) STAT3. The relative protein levels of (H) Bcl-2, (I) Bax, (J) cleaved caspase-3, (K) p-STAT3 and (L) STAT3 were calculated and presented as the fold-change. Experiments were repeated three times. Data are reported as the mean ± standard deviation. **P<0.01 vs. control siRNA group. IL, interleukin; siRNA, small interfering RNA.
Figure 5. Effects of IL-22 on cell viability, apoptosis and the STAT3 signaling pathway in MG63 cells. MG63 cells were transfected with the IL-22 over-expression or control plasmid for 48 h. (A) The MTT assay was used to detect cell viability. (B) Flow cytometry was used to detect cell apoptosis and to calculate the apoptosis rate. (C) Western blotting was used to detect the protein expression of Bcl-2, Bax, cleaved caspase-3, p-STAT3 and STAT3. Reverse transcription-quantitative PCR was used to detect the mRNA expression level of (E) Bcl-2, (F) Bax and (G) STAT3. Reverse Bcl-2, Bax, cleaved caspase-3, p-STAT3 and STAT3 protein levels were calculated and presented as the fold-change. Experiments were repeated three times. Data are reported as the mean ± standard deviation. **P<0.01 vs. control plasmid group.
study (10). The ability of IL-22 to regulate the sensitivity of osteosarcoma cells to cisplatin and its molecular mechanism was also investigated. The downregulation of IL-22 significantly decreased the IC$_{50}$ value of DDP in MG63/DDP cells, decreased the viability of MG63/DDP cells, induced apoptosis, decreased the expression of BCL-2 and promoted the expression of Bax and cleaved caspase-3. The overexpression of IL-22 significantly increased the IC$_{50}$ value of DDP in MG63 cells, increased MG63 cell viability, inhibited apoptosis, increased BCL-2 expression and decreased expression of Bax and cleaved caspase-3. This indicated that IL-22 could affect the sensitivity of osteosarcoma cells to cisplatin. The increased expression of IL-22 significantly decreased the sensitivity of osteosarcoma cells to cisplatin, whereas decreased IL-22 expression significantly increased the sensitivity of osteosarcoma cells to cisplatin.

The PI3K/AKT signaling pathway is thought to be one of the most important oncogenic pathways in human osteosarcoma, and plays a fundamental role in maintaining cell viability (19,20). The JAK/STAT signaling pathway is involved in several cellular processes, including cell proliferation, apoptosis and differentiation (21). JAK2 acts as an upstream kinase to recruit STAT3 monomers in the cytosol, allowing inactive STAT3 to form active dimers that are transferred to the nucleus and bind to DNA, leading to the transcription of target genes (22,23). The activation of JAK2/STAT3 has been implicated in the development and progression of various tumors (24-27).

IL-22 has been reported to activate the STAT3 signaling pathway in cells and initiate downstream transduction signals (28-30), including in osteosarcoma cells (10). Therefore, the present investigated the effect of IL-22 expression on the STAT3 signaling pathway in DDP-treated osteosarcoma cells. IL-22 downregulation led to significantly decreased expression of p-STAT3 in MG63/DDP cells, and IL-22 overexpression caused significantly increased expression of p-STAT3 in MG63 cells. This indicated that IL-22 overexpression activated the STAT3 signaling pathway, which was consistent with a previous study (10). The present study suggested that IL-22 may affect cisplatin resistance in osteosarcoma cells by regulating the STAT3 signaling pathway.

The present study was only a preliminary investigation into the role of IL-22 in regulating the sensitivity of osteosarcoma cells to cisplatin. The present study had certain limitations, and further detailed studies are required to improve the understanding on the role of IL-22 in the sensitivity of osteosarcoma cells to cisplatin. Furthermore, the effects of overexpressing IL-22 in MG63/DDP cells should be investigated. The association between the IL-22 expression level and the IC$_{50}$ of cisplatin in osteosarcoma cell lines should also be determined. Besides, in vivo studies should also be conducted in the future.

Overall, the present study indicated that IL-22 regulates cell viability and apoptosis of osteosarcoma cells by regulating the activation of the STAT3 signaling pathway and the expression of apoptosis-associated genes, thereby affecting the sensitivity of osteosarcoma cells to cisplatin. The findings of the present study indicate that IL-22 might be a novel potential diagnostic biomarker and therapeutic target of osteosarcoma. In addition, the present study provided theoretical and experimental basis for the development of a novel type of sensitizer with decreased chemotherapeutic doses of DDP, improved therapeutic effect and decreased adverse reactions.

Acknowledgements

Not applicable.

Funding

The present study was supported by Youth Science and Technology Project Of Suzhou (grant no. KJXW2018023).

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions

ZL contributed to data collection, statistical analysis, data interpretation and manuscript preparation. RX, XZ, JS, GC and TZ contributed to data collection and statistical analysis. XY contributed to data collection, statistical analysis and manuscript preparation. All authors read and approved the final manuscript.

Ethics approval and consent to participate

The current study was approved by The Institutional Review Board of The Suzhou Municipal Hospital (China) and patients provided written informed consent.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Ben M’na A, Chelly I, Souissi A, Azzouz H, Haouet S, Mokni M, Khchir N and Ben Osman A: Primary cutaneous osteosarcoma. Ann Dermatol Venereol 140: 206-208, 2013 (In French).
2. Osborne TS and Khanna C: A review of the association between osteosarcoma metastasis and protein translation. J Comp Pathol 146: 132-142, 2012.
3. Meyers PA: Muramyl tripeptide (mifamurtide) for the treatment of osteosarcoma. Expert Rev Anticancer Ther 9: 1035-1049, 2009.
4. Taran SJ, Taran R and Malipatil NB: Pediatric osteosarcoma: An updated review. Indian J Med Paediatr Oncol 38: 33-43, 2017.
5. Harrison DJ, Geller DS, Gill JD, Lewis VO and Gorlick R: Current and future therapeutic approaches for osteosarcoma. Expert Rev Anticancer Ther 18: 39-50, 2018.
6. Hattinger CM, Panelli M, Tavanti E, Vella S, Ferrari S, Picci P and Serra M: Advances in emerging drugs for osteosarcoma. Expert Opin Emerg Drugs 20: 495-514, 2015.
7. Li S, Sun W, Wang H, Zuo D, Hua Y and Cai Z: Research progress on the multidrug resistance mechanisms of osteosarcoma chemotherapy and reversal. Tumour Biol 36: 1329-1338, 2015.
8. Dumoutier L, Louahed J and Renaud JC: Cloning and characterization of IL-10-related T cell-derived inducible factor (IL-TIF), a novel cytokine structurally related to IL-10 and inducible by IL-9. J Immunol 164: 1814-1819, 2000.
9. Zindl CL, Lai JF, Lee YK, Maynard CL, Harbour SN, Ouyang W, Chaplin DD and Weaver CT: IL-22-producing neutrophils contribute to antimicrobial defense and restitution of colonic epithelial integrity during colitis. Proc Natl Acad Sci USA 110: 12768-12773, 2013.

10. Li P, Shi X, Xu Y, Zhong B, Lu Y and Sun Y: Interleukin-22 promotes osteosarcoma cell proliferation and invasion via STAT3 activation. Med Sci Monit 24: 7802-7808, 2018.

11. Liu Q and Wang K: The induction of ferroptosis by impairing STAT3/Nrf2/GPx4 signaling enhances the sensitivity of osteosarcoma cells to cisplatin. Cell Biol Int 43: 1245-1256, 2019.

12. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25: 402-408, 2001.

13. Chen C, Zhao M, Tian A, Zhang X, Yao Z and Ma X: Aberrant activation of Wnt/β-catenin signaling drives proliferation of bone sarcoma cells. Oncotarget 6: 17570-17583, 2015.

14. Li QC, Xu H, Wang X, Wang T and Wu J: miR-34a increases cisplatin sensitivity of osteosarcoma cells in vitro through up-regulation of c-Myc and Bim signal. Cancer Biomark 21: 135-144, 2017.

15. Waidmann O, Kronenberger B, Scheiermann P, Köberle V, Mühl H, Piiper A: Interleukin-22 serum levels are a negative prognostic indicator in patients with hepatocellular carcinoma. Hepatology 59: 1207, 2014.

16. Yi J, Shi X, Xu Y, Zhong B, Shi Y, Lu Y and Sun Y: Interleukin-22 promotes osteosarcoma cell proliferation and invasion via STAT3 activation. Med Sci Monit 24: 7802-7808, 2018.

17. Wang X, Xu J, Chen J, Jin S, Yao J, Yu T, Wang W and Guo R: IL-22 confers EGFR-TKI resistance in NSCLC via the AKT and ERK signaling pathways. Front Oncol 9: 1167, 2019.

18. Rudloff I, Jarde T, Bachmann M, Elgass KD, Kerr G, Engel R, Richards E, Oliva K, Wilkins S, McMurrick PJ, et al: Molecular signature of interleukin-22 in colon carcinoma cells and organoid models. Transl Res: Oct 31, 2019.

19. Graziano AC, Cardile V, Avola R, Vicario N, Parenti C, Salvatorelli L, Magro G and Parenti R: Wilms’ tumor gene 1 silencing inhibits proliferation of human osteosarcoma MG-63 cell line by cell cycle arrest and apoptosis activation. Oncotarget 8: 13917-13931, 2017.

20. Perry JA, Kiezena A, Tonzi P, Van Allen EM, Carter SL, Baca SC, Cowley GS, Bhatt AS, Rheinbay E, Pedamallu CS, et al: Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma. Proc Natl Acad Sci USA 111: E5564-E5573, 2016.

21. Tang H and Xue G: Major physiological signaling pathways in the regulation of cell proliferation and survival. Handb Exp Pharmacol 249: 13-30, 2018.

22. Lou L, Zhou J, Liu Y, Wei YI, Zhao J, Deng J, Dong B, Zhu L, Wu A, Yang Y and Chai L: Chlorogenic acid induces apoptosis to inhibit inflammatory proliferation of IL-6-induced fibroblast-like synoviocytes through modulating the activation of JAK/STAT and NF-κB signaling pathways. Exp Ther Med 11: 2054-2060, 2016.

23. Li HX, Zhao W, Shi Y, Li YN, Zhang LS, Zhang HQ and Wang D: Retinoic acid amide inhibits JAK/STAT pathway in lung cancer which leads to apoptosis. Tumour Biol 36: 8671-8678, 2015.

24. Donegan JJ, Patton MS, Chavera TS, Berg KA, Morilik DA and Girotti M: Interleukin-6 attenuates serotonin 2A receptor signaling by activating the JAK-STAT pathway. Mol Pharmacol 87: 492-500, 2015.

25. Zhu Z, Lu X, Jiang L, Sun X, Zhou H, Jia Z, Zhang X and Ma L: STAT3 signaling pathway is involved in decitabine induced biological phenotype regulation of acute myeloid leukemia cells. Am J Transl Res 7: 1896-1907, 2015.

26. Kim BH, Yi EH and Ye SK: Signal transducer and activator of transcription 3 as a therapeutic target for cancer and the tumor microenvironment. Arch Pharm Res 39: 1085-1099, 2016.

27. Villarino AV, Kanno Y, Ferdinand JR and O’Shea JJ: Mechanisms of Jak/STAT signaling in immunity and disease. J Immunol 194: 21-27, 2015.

28. Bi Y, Cao J, Jin S, Lv L, Qi L, Liu F, Geng J and Yu Y: Interleukin-22 promotes lung cancer cell proliferation and migration via the IL-22R1/STAT3 and IL-22R1/AKT signaling pathways. Mol Cell Biochem 415: 1-11, 2016.

29. Yu J, Xiao Z, Zhao R, Lu C and Zhang Y: Paeoniflorin suppressed IL-22 via p38 MAPK pathway and exerts anti-psoriatic effect. Life Sci 180: 17-22, 2017.

30. Basu R, O’Quinn DB, Silberberger DJ, Schoeb TR, Fouser L, Ouyang W, Hatton RD and Weaver CT: TH22 cells are an important source of IL-22 for host protection against enteropathogenic bacteria. Immunity 37: 1061-1075, 2012.